Drugs that contain Gadofosveset Trisodium
1. Ablavar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7011815 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
Feb, 2015
(9 years ago) | |
| US8394356 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
Feb, 2015
(9 years ago) | |
| US7229606 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2015
(8 years ago) | |
| US8017105 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2015
(8 years ago) | |
| US7060250 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2015
(8 years ago) | |
| US6676929 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2013 |
NCE-1 date: 22 December, 2012
Market Authorisation Date: 22 December, 2008
Treatment: Method of mr imaging of a mammal
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
ABLAVAR family patents
